TY - JOUR T1 - A Retrospective Analysis of Perioperative Chemotherapy and Coronavirus Disease in Patients With Breast Cancer JF - Anticancer Research JO - Anticancer Res SP - 2193 LP - 2195 DO - 10.21873/anticanres.14994 VL - 41 IS - 4 AU - KAZUMI HAYASHI AU - MIHO TAMURA AU - EIJIRO NAGASAKI AU - YUKIKO YOSHII AU - TAKAYUKI ISHIGAKI AU - TAKASHI KAZAMA AU - MAKIKO KAMIO AU - HIROKO NOGI AU - YASUO TORIUMI AU - HIROSHI TAKEYAMA AU - SHINGO YANO Y1 - 2021/04/01 UR - http://ar.iiarjournals.org/content/41/4/2193.abstract N2 - Background/Aim: Since January 2020, coronavirus disease (COVID-19) cases have been confirmed in Japan, and the number of patients with COVID-19 has been increasing. Two emergency declarations have been made previously and one is currently in effect. Based on our experience of a situation that could affect cancer treatment, this study retrospectively examined the correlation between perioperative anticancer therapy and COVID-19 incidence in patients with breast cancer. Patients and Methods: Patients who underwent perioperative anticancer therapy for breast cancer at our hospital from February 2020 to February 2021 were included in this study. The presence or absence of COVID-19, timing of anticancer drug initiation, and clinical data were collected. Results: No cases of COVID-19 were diagnosed in patients receiving perioperative anticancer therapy at our hospital. Conclusion: Regimen modification, active use of supportive care, and patient lifestyle were factors reducing the incidence of COVID-19. ER -